Pfizer Supports Patients Affected by Rare Diseases
Reprint from Pfizer.com
Rare Disease Day 2014 encourages the rare disease community to Join Together for Better Care. On Feb 28, Pfizer proudly joins the European Organization for Rare Diseases (EURORDIS), the National Organization for Rare Disorders (NORD), as well as a coalition of patient organizations, professional societies, government agencies, researchers and biopharmaceutical companies supporting the urgent need to raise awareness of rare diseases and their impact on patients across the globe.
Fewer than five percent of all rare diseases currently have approved treatments,1 leaving millions of patients around the world without therapies needed to manage their disease. Many of these diseases are serious and life threatening.
“As one of the world’s largest biopharmaceutical companies with dedicated colleagues across research, medicine development and commercialization for rare disease treatments, we are uniquely positioned to help address the unmet needs of this community,” said Bert Bruce, Vice President, Rare Disease Commercial Development, Pfizer.
Recognizing the challenges patients face beyond obtaining access to treatment for rare diseases, Pfizer will continue to work with patient advocacy groups to raise awareness of rare diseases, aid in diagnosis, ensure access to treatments, and advocate for supportive policy, regulatory, and reimbursement environments.
“We are proud of our team’s deep knowledge of clinical development and commitment to rare diseases, but we recognize that we can’t do this alone,” said Brenda Cooperstone, Vice President, Medicines Development Group, Pfizer. “We believe collaboration is critical to success.”
Pfizer believes that patients suffering from rare diseases deserve the same access to medicines as those suffering from more common conditions, and remains committed to finding therapies for the remission and relief of serious illness and working towards eradication, regardless of prevalence.
With more than a decade of experience in rare disease product development, Pfizer has 22 medicines approved worldwide to treat rare diseases in the areas of hematology, neuroscience, inherited metabolic disorders, pulmonology, and oncology, and continues to actively build the rare disease pipeline.
“Pfizer is committed to investing in the development of new rare disease therapies,” said Kevin Lee, Chief Scientific Officer, Rare Disease Research Unit, Pfizer. “I want to thank our researchers and partners for their dedication to the discovery and development of innovative medicines.”
This year, Pfizer colleagues are participating in Rare Disease Day initiatives across the globe. To show your support, raise and join hands with rare disease patients around the world at rarediseaseday.org/join-your-hands/.